Frost & Sullivan

MARCH 22, 2024

As of April 2023, the global pharmaceutical R&D pipeline has over 6000 molecules in active clinical development phase, showing a 5.8% growth from 2023 to 2024. What is driving transformation in the pharma industry? increase from 2022. However, the pharma/biopharma industry shows overall stagnant R&D activity.

Ecosystems 52

Ecosystems Biopharma Biotech Contract research organization 52

Frost & Sullivan

FEBRUARY 15, 2024

Let us coach you on your transformational journey, while we actively support you in fostering collaborative initiatives within your industry’s ecosystem. Small- to mid-sized pharma/biotech players in APAC are rivaling Europe in clinical trials through multiple CRO partnerships in the region, tapping into a population-rich landscape.

Ecosystems 40

Ecosystems Contract research organization Biotech Utilities 40

Frost & Sullivan

APRIL 25, 2023

April 25, 2023 – Frost & Sullivan researched the contract research organizations industry and, based on its analysis results, recognizes Emmes with the 2023 Global Competitive Strategy Leadership Award. SAN ANTONIO, TX.

Biopharmaceuticals 52

Biopharmaceuticals Biopharma Biotechnology Contract research organization 52

IBM Business Partners

MAY 6, 2024

The FDA, in its May 2023 draft guidance, backed the adoption of DCTs across drugs, biologics and medical devices , highlighting their merits such as enhanced patient convenience, diminished caregiver burden, broader access to varied demographics, amplified trial productivity, and support for research on rare or mobility-restricted patient groups.

Partnering capability and readiness 57

Partnering capability and readiness Biopharma Contract research organization Collaboration 57